Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


R2's ImageChecker CAD Unanimously Endorsed By Radiology Panel

This article was originally published in The Gray Sheet

Executive Summary

R2 Technology's ImageChecker M1000 could identify and mark for further review 31-44% more potentially positive mammograms than would currently be identified, William Sacks, a medical officer in FDA's Office of Device Evaluation, said at a Radiological Devices Advisory Panel meeting in Rockville, Maryland.

You may also be interested in...

Fischer Taking Chance With SenoScan 510(k), Leaving PMA Route Open

Fischer Imaging's premarket notification submission for the SenoScan full-field digital mammography system is readily convertible into a PMA, should FDA reject the 510(k) approach for the device, as the agency has done in the past.

Aker BioMarine Plans US NDI Notification For EPA/DHA Formulated To Pass Blood-Brain Barrier

Aker BioMarine seeks supplement firms to use its EPA/DHA innovation bound by lysophosphatidylcholine to enable the fatty acids to pass through the blood-brain and blood-retinal barriers and boost of eye and brain health benefits. It will submit an NDI notificaion in the US during 2022.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts